The latest on how to keep VIP on the FDA registry of drugs that may be compounded
As many of you know, there has been concern in the chronic inflammatory response syndrome (CIRS) community regarding the recent publication from the FDA (9/4/19) stating that the FDA will not include VIP on the registry of drugs that may be compounded. This decision is in follow up to a similar opinion from February 2019, which in turn was the result of a decision made by the FDA, November 3, 2016 to remove VIP from a list of drugs that can be compounded.
VIP was first used in CIRS patients in November, 2008. Its use has revolutionized care of CIRS in that not only does VIP correct symptoms and proteomics seen in affected patients, but it also corrects gray matter nuclear atrophy (think of early Alzheimer’s!) and the transcriptomic (gene activation and suppression) abnormalities that are the ultimate source of this illness. Without VIP, patients will be forced to either suffer needlessly (this illness can kill people too) or search for another neuroregulatory peptide that can safely reproduce the extraordinary benefits of VIP.
In the years since VIP was first used, it has been estimated that over 1000 physicians have prescribed VIP as a nasal spray for over 10,000 patients from at least five pharmacies. VIP has an impeccable safety record. For best results, we suggest that published criteria for safe use of VIP be followed.
What can we do to stop this proposed regulatory change? There are three different approaches that potentially could maintain current usage status of VIP.
Click the articles below for more information on how to donate or to make your voice heard: